CoxaPro
> Clinical Library > Welcome to the joint replacement clinical library > Oxidized zirconium femoral component for TKA: A follow-up note of a previous report at a minimum of 10years
The Knee, ISSN: 1873-5800, Vol: 21, Issue: 4, Page: 858-61
Knee
Link to article
Oxidized zirconium femoral component for TKA: A follow-up note of a previous report at a minimum of 10years
Innocenti, Massimo; Matassi, Fabrizio; Carulli, Christian; Nistri, Lorenzo; Civinini, RobertoKnee
Background
New bearing surfaces for total knee replacement have been described in an attempt to reduce polyethylene wear and secondary osteolysis and improve longevity of implants. Oxidized zirconium is a new material that combines the strength of a metal with the wear properties of a ceramic. However, there are no reports as to who documents the long term results. We report a 10 year follow-up note of a selected series of TKAs with an oxidized zirconium femoral component.
Methods
We prospectively follow 98 TKAs performed in 94 patients with an oxidized zirconium femoral component. Five patients (5 knees) had died and 6 (6 knees) were lost to follow-up at a minimum of 2 years (mean, 6.3 years; range, 2–9 years) after the operation. For the remaining 83 patients (87 knees), the minimum follow-up was 10 years (mean, 11.3 years; range, 10.0–12.6 years). In 51 cases (58.6%), a cruciate-retaining implant with a deep-dished, more conforming PE was used, and in 36 cases (41.4%), a posterior-stabilized design was used. The patellae were resurfaced in 32 cases (36.7%) and in 55 cases (63.3%) were left unresurfaced.
Results
Survivorship was 97.8% at 10 years postoperatively. Two knees were revised for aseptic loosening of the femoral component. No major complication was observed clinically or radiologically. Mean Knee Society score improved from 36 to 84 and functional score from 37 to 83.
Conclusions
Oxidized zirconium femoral component in TKA performs well over the first 10 years following implantation, with excellent survival rates and good clinical and radiological outcomes.
Level of evidence
Level IV, therapeutic study.
Link to article